Clinical outcomes in women with endometrial polyps underwent conservative management

Taiwan J Obstet Gynecol. 2023 Jul;62(4):553-558. doi: 10.1016/j.tjog.2022.08.022.

Abstract

Objective: To evaluate the regression rate of endometrial polyps (EPs) in a cohort of asymmetric women after conservative follow-up.

Materials and methods: In this retrospective cohort study, a total of 1006 women with asymptomatic EPs were treated with expectant management or hormonal drugs between June 1999 and May 2018. Four hundred forty-eight women (44.5%) were administered with hormonal medications and 558 women were managed expectantly (55.5%). Office hysteroscopy was performed to confirm the diagnosis and regression of EPs. Hormonal administration included oral contraceptives, progestin and cyclic estrogen/progestin regimen according to physicians' preferences. Clinical characteristics, including the patient's age, body mass index, parity, and type of conservative management were collected.

Results: The mean observation time was 14.1 ± 18.5 months (range, 1-162 months). The overall regression rate of EPs in this cohort was 33.5%, 24.6% occurred after medication and 8.9% after expectant management. Patient age (<50 years) (p < 0.001), follow-up period (p = 0.005) and hormonal drugs used (p < 0.001) were significantly associated with EP regression. Twenty-four (7.1%) of the 337 EP regression patients later developed recurrent disease. Follow-up period (p < 0.001) and hormonal drugs used (p = 0.032) were closely related to polyp recurrence after initial regression. Nevertheless, multivariate logistic regression analysis revealed that hormonal drugs used was significantly associated with the regression (p < 0.001) and recurrence (p = 0.016) of EPs.

Conclusion: Women aged 50 or less are more suitable for conservative treatment for EPs. Hormonal drugs used could increase the incidence of EP regression.

Keywords: Conservative; Endometrial polyp; Hysteroscopy; Recurrence; Regression.

MeSH terms

  • Conservative Treatment
  • Endometrial Neoplasms* / diagnosis
  • Female
  • Humans
  • Hysteroscopy
  • Polyps* / diagnosis
  • Polyps* / therapy
  • Pregnancy
  • Progestins / therapeutic use
  • Retrospective Studies
  • Uterine Neoplasms* / complications

Substances

  • Progestins